Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNTI Senti Biosciences, Inc.

Trading 06-08 15:16:29 EDT

0.9570

-0.0084

-0.87%

High0.9798	Low0.9433	Vol93.16K
Open0.9600	D1 Closing0.9654	Amplitude3.78%
Mkt Cap29.81M	Tradable Cap13.95M	Total Shares31.14M
T/O89.30K	T/O Rate0.64%	Tradable Shares14.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNTI","market":"US","secType":"STK","nameCN":"Senti Biosciences, Inc.","latestPrice":0.957,"timestamp":1780946132651,"preClose":0.9654,"halted":0,"volume":93163,"delay":0,"changeRate":-0.008701056556867696,"floatShares":14577400,"shares":31144500,"eps":-1.9197,"marketStatus":"Trading","change":-0.0084,"latestTime":"06-08 15:16:29 EDT","open":0.96,"high":0.9798,"low":0.9433,"amount":89297.7882419,"amplitude":0.037808,"askPrice":0.9563,"askSize":100,"bidPrice":0.95,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":-1.9197,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1780948800000},"marketStatusCode":2,"adr":0,"listingDate":1622001600000,"exchange":"NASDAQ","adjPreClose":0.9654,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":0.9654,"latestTime":"09:25 EDT","volume":637,"amount":610.57218859,"timestamp":1780925116541,"change":0.0046,"changeRate":0.004765,"amplitude":0.040812},"postHourTrading":{"tag":"盘后","latestPrice":0.9461,"preClose":0.9654,"latestTime":"19:23 EDT","volume":1340,"amount":1270.1432,"timestamp":1780701795642,"change":-0.0193,"changeRate":-0.019992,"amplitude":0.019992},"volumeRatio":0.499091},"requestUrl":"/m/hq/s/SNTI/wiki","defaultTab":"wiki","newsList":[{"id":"2638540320","title":"Senti Biosciences unit issues USD 10 million senior secured convertible notes to Celadon Partners SPV 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540320?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:03","pubTimestamp":1779825793,"startTime":"0","endTime":"0","summary":"Senti Biosciences Holdings’ subsidiary Senti Holdings sold USD 10 million of Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026.Acquiom Agency Services was appointed collateral agent for the notes in connection with the May 20 issuance.Senti entered registration rights, guarantee, and voting agreements tied to the financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL70WXVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636969018","title":"Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636969018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636969018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:40","pubTimestamp":1779036031,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","SNTI","XBI","LU0128526141.USD","IE00B4R5TH58.HKD","BK4539","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4581","IE0034235188.USD","BK4231","BK4505","BK4588","BK4585","IE0009355771.USD","BK4137","LU0029874061.USD","XLV","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","HCSG","LU2324357040.USD","BK4080","ALX","ARGX","LABU","IE0002141913.USD","LU1983260115.SGD","ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635057876","title":"Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2635057876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635057876?lang=en_us&edition=fundamental","pubTime":"2026-05-16 14:00","pubTimestamp":1778911225,"startTime":"0","endTime":"0","summary":"Senti Biosciences, Inc. (SNTI) has disclosed a new risk, in the Debt & Financing category. Senti Biosciences, Inc. faces considerable refinancing a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908428","title":"Senti Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635908428?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 08:27 ET (12:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081089","title":"Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081089","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:05","pubTimestamp":1778846737,"startTime":"0","endTime":"0","summary":"Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710552","title":"Senti Biosciences Q1 net loss narrows on cost reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710552","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710552?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:54","pubTimestamp":1778763295,"startTime":"0","endTime":"0","summary":"Senti Biosciences Q1 net loss narrows on cost reductionOverviewUS biotechnology firm's Q1 revenue beat analyst expectationsNet loss narrowed yr/yr, aided by $6.9 mln gain from lease modificationOutloo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635271037","title":"BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635271037","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635271037?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:51","pubTimestamp":1778763086,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy May 14 (Reuters) - Senti Biosciences Holdings Inc SNTI.O:SENTI BIOSCIENCES HOLDINGS ANN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635103217","title":"Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2635103217","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635103217?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:46","pubTimestamp":1778762808,"startTime":"0","endTime":"0","summary":"Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52558096/senti-biosciences-q1-eps-0-14-beats-0-36-estimate-sales-16-000k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710317","title":"Senti Biosciences Holdings Inc: Q1 Net Loss per Share $0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710317?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX590F4A:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710850","title":"Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710850","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710850?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762700,"startTime":"0","endTime":"0","summary":"Secured strategic financing vehicle for up to $40 million. Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn. SOUTH SAN FRANCISCO, Calif., May 14, 2026  -- Senti Biosciences Holdings, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.In addition, Senti announced that it identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50%  of the patients achieving a composite CR  when they received any SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1. The Donor X attribute is found in 50% of","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","LU1363072403.SGD","BK4006","BK4588","LU2237443465.HKD","BK4139","IE00BFXG1179.USD","LU0971096721.USD","BK4539","LU2746668974.SGD","BK4183","LU0149725797.USD","IE0009354923.USD","LU2237443549.SGD","LU0170899867.USD","LU2746668461.USD","LU0267386448.USD","IE00BKVL7J92.USD","SNTI","ODD","IE00BHPRN162.USD","BK4585","LU2237443978.SGD","LU2237443622.USD","LU2237443895.HKD","IE00B1BXHZ80.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU2237443382.USD","CMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771740","title":"Senti Biosciences Holdings Announces Positive FDA Rmat Meeting on Registrational Clinical and Cmc Strategy for Senti-202 in Relapsed/Refractory Aml, Along With Important Efficacy and Durability Updates on the Senti-202 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771740?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717201","title":"Senti Biosciences Holdings Inc - Senti-202 Future Manufacturing to Use Donor X Phenotype","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717201?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634246745","title":"Senti Biosciences deregisters common stock under Exchange Act Form 15","url":"https://stock-news.laohu8.com/highlight/detail?id=2634246745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634246745?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:18","pubTimestamp":1778275091,"startTime":"0","endTime":"0","summary":"Senti Biosciences Inc filed to deregister its Common Stock, par value $0.0001 per share.Filing dated May 8, 2026 followed an April 24, 2026 holding company reorganization that converted each share of Senti common stock into one share of Senti Biosciences Holdings common stock with the same rights.Holders of record for Senti common stock were listed as 1 as of the notice date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL4BzmK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632564201","title":"Senti Biosciences Inc - Enters Agreement to Issue up to $40 Mln in Senior Secured Convertible Notes - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2632564201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632564201?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:09","pubTimestamp":1777666150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nFWN41E0YG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647851","title":"Senti Biosciences signs securities purchase deal for up to $40 million convertible notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647851","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647851?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:08","pubTimestamp":1777666114,"startTime":"0","endTime":"0","summary":"Senti Biosciences entered securities purchase agreement on April 27, 2026 for private placement of up to USD 40 million of Senior Secured Convertible Notes issued by subsidiary Senti Holdings.Initial tranche set at USD 10 million, subject to closing conditions that include completion of holding company reorganization completed on April 24, 2026.Second tranche may add up to USD 30 million, subject to Celadon election and execution of definitive documents within 30 days for potential CVR transaction tied to SENTI-202 milestones.Notes mature six months after initial closing date, with cash repayment set at 200% of outstanding principal if not converted or exchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDLc4Yhb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627455375","title":"Senti Bio CEO Timothy Lu to present logic-gated NK cell therapy at AACR meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627455375?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:03","pubTimestamp":1776085439,"startTime":"0","endTime":"0","summary":"Senti Biosciences CEO Timothy Lu will present at AACR Annual Meeting 2026 in San Diego on April 17, 2026.Talk will cover logic-gated engineered NK cell therapy SENTI-202, including clinical trial results in relapsed or refractory acute myeloid leukemia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL5QLxR6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4539","BK4139","SNTI","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624820542","title":"BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624820542","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624820542?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:31","pubTimestamp":1775079101,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC FilingApril 1  - Senti Biosciences, Inc SNTI.O:SENTI BIOSCIENCES INC - ANNOUNCES HOLDING COMPANY REORGANIZATION EFFECTIVE BY APRIL 16, 2026 - SEC FILINGSENTI BIOSCIENCES, INC: UPON EFFECTIVENESS OF HOLDING COMPANY REORGANIZATION, SENTI BIOSCIENCES HOLDINGS WOULD BECOME SUCCESSOR ISSUER TO COSource text: [ID:n0001628280-26-022824]Further company coverage: SNTI.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0X8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2624541678","title":"Senti Biosciences plans tax-free holding company reorganization by April 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541678","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541678?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:34","pubTimestamp":1775075673,"startTime":"0","endTime":"0","summary":"Senti Biosciences announced plans to implement a holding-company reorganization, targeted to take effect by April 16, 2026.Transaction structure calls for a tax-free merger into a newly formed merger subsidiary under newly created parent Senti Biosciences Holdings.Existing common shares will automatically convert on a 1-for-1 basis into shares of Senti Biosciences Holdings with equivalent rights.Nasdaq trading is expected to continue under ticker SNTI on an uninterrupted basis, with a new CUSIP.Reorganization is not expected to change directors, management, assets, or operations on a consolidated basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLMSdBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515011","title":"Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515011?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:45","pubTimestamp":1775047521,"startTime":"0","endTime":"0","summary":"Senti Biosciences announced publication in Cell Systems on April 1, 2026, outlining a logic-gated CAR design framework intended to improve safety and precision of engineered cell therapies.Preclinical findings showed NOT-gated CAR designs could help immune cells eliminate tumor cells while sparing healthy tissue, supporting a broader therapeutic window where clean tumor-specific targets are limited.Research also indicated optimized designs may reduce cell exhaustion and sustain anti-cancer activity with repeat exposure, which could improve durability of responses.Company filed a patent application covering aspects of technology described in study, positioning Gene Circuit platform for wider use across CAR T and CAR NK modalities.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5QDq0S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4539","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","SNTI","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317550","title":"Senti Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317550","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317550?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 08:07 ET (12:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sentibio.com","stockEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.0005},{"period":"6month","weight":-0.5468},{"period":"1year","weight":-0.7288},{"period":"ytd","weight":-0.0717}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.037903},{"month":2,"riseRate":0.2,"avgChangeRate":-0.117173},{"month":3,"riseRate":0.2,"avgChangeRate":-0.07377},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016933},{"month":5,"riseRate":0.4,"avgChangeRate":-0.057207},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.248747},{"month":7,"riseRate":0.4,"avgChangeRate":0.120052},{"month":8,"riseRate":0.4,"avgChangeRate":-0.119944},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088688},{"month":10,"riseRate":0.6,"avgChangeRate":0.032318},{"month":11,"riseRate":0.4,"avgChangeRate":0.12033},{"month":12,"riseRate":0.4,"avgChangeRate":0.047383}],"exchange":"NASDAQ","name":"Senti Biosciences, Inc.","nameEN":"Senti Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Senti Biosciences, Inc.,SNTI,Senti Biosciences, Inc.股票,Senti Biosciences, Inc.股票老虎,Senti Biosciences, Inc.股票老虎国际,Senti Biosciences, Inc.行情,Senti Biosciences, Inc.股票行情,Senti Biosciences, Inc.股价,Senti Biosciences, Inc.股市,Senti Biosciences, Inc.股票价格,Senti Biosciences, Inc.股票交易,Senti Biosciences, Inc.股票购买,Senti Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction